Assessment of preclinical atherosclerosis in patients with ankylosing spondylitis

Journal of Rheumatology

Volumn 39, Issue 2, 2012, Pages 322-326

  Hamdi, Wafa ^a   Bouaziz, Mouna Chelli ^a   Zouch, Imen ^a   Ghannouchi, Mohamed Mehdi ^a   Haouel, Manel ^a   Ladeb, Mohamed Fethi ^a   Kchir, Mohamed Montacer ^a  

^a Institut National Mohammed Kassab d'Orthopedie   (Tunisia)

Author keywords

Ankylosing spondylitis; Atherosclerosis; Intima media thickness; Risk factors; Ultrasound

Indexed keywords

C REACTIVE PROTEIN; DICLOFENAC; ETANERCEPT; HLA B27 ANTIGEN; INDOMETACIN; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID;

ADULT; ANKYLOSING SPONDYLITIS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY; CONTROLLED STUDY; DISEASE SEVERITY; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOLOGIST; RISK ASSESSMENT; SCORING SYSTEM;

ADULT; AGE OF ONSET; ATHEROSCLEROSIS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; FEMALE; HLA-B27 ANTIGEN; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING;

EID: 84856552539     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110792     Document Type: Article

References (36)

1. Lautermann D, Braun J. Ankylosing spondylitis - cardiac manifestations. Clin Exp Rheumatol 2002;20:S11-5.
2. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993;52:174-6. (Pubitemid 23094303)
3. Radford EP, Doll R, Smith PG. Mortality among patients with ankylosing spondylitis not given X-ray therapy. N Engl J Med 1977;11:572-6. (Pubitemid 8197336)
4. Kaprove RE, Little AH, Graham DC, Rosen PS. Ankylosing spondylitis: Survival in men with and without radiotherapy. Arthritis Rheum 1980;23:57-61. (Pubitemid 10214770)
5. Heeneman S, Daemen MJ. Cardiovascular risks in spondyloarthritides. Curr Opin Rheumatol 2007;19:358-62. (Pubitemid 46884191)
6. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72. (Pubitemid 44749774)
7. Rodrigues Pereira RM, De Carvalho JF, Bonfá E. Metabolic syndrome in rheumatological diseases. Autoimmun Rev 2009;8:415-9.
8. Symmons DP, Goodson NJ, Cook MN, Watson DJ. Men with ankylosing spondylitis have an increased risk of myocardial infarction [abstract]. Arthritis Rheum 2004;50 Suppl:S477.
9. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14-22. (Pubitemid 29024679)
10. Gonzalez-Juanatey C, Llorca J, Martin J, Gonzalez-Gay MA. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 2009;38:366-71.
11. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8. (Pubitemid 14134775)
12. Stein JH, Douglas PS, Srinivasan SR, Bond MG, Tang R, Li S, et al. Distribution and cross-sectional age-related increases of carotid artery intima-media thickness in young adults: The Bogalusa Heart Study. Stroke 2004;35:2782-7. (Pubitemid 39565171)
13. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Desvarieux M, et al. Advisory Board of the 3rd Watching the Risk Symposium 2004, 13th European Stroke Conference. Mannheim intima-media thickness consensus. Cerebrovasc Dis 2004;18:346-9.
14. van Sijl AM, Peters MJ, Knol DK, de Vet HC, Gonzalez-Gay MA, Smulders YM, et al. Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: A meta-analysis. Semin Arthritis Rheum 2011;40:389-97.
15. Cacciapaglia F, Zardi EM, Coppolino G, Buzzulini F, Margiotta D, Arcarese L, et al. Stiffness parameters, intima-media thickness and early atherosclerosis in systemic lupus erythematosus patients. Lupus 2009;18:249-56.
16. Peters MJ, van Eijk IC, Smulders YM, Serne E, Dijkmans BA, van der Horst-Bruinsma IE, et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010;37:161-6.
17. Bodnar N, Kerekes G, Seres I, Paragh G, Kappelmayer J, Nemethne ZG, et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol 2011;38:723-9.
18. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Dierssen T, Vaqueiro I, Blanco R, et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine 2009;88:358-65.
19. Choe JY, Lee MY, Rheem I, Rhee MY, Park SH, Kim SK. No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 2008;75:548-53.
20. Belloli L, Massarotti M, Marasini B. Risk factors of atherosclerosis in patients with spondylarthropathies: comment on the article by Gonzalez-Juanatey, et al. Arthritis Rheum 2008;59:455. (Pubitemid 351399218)
21. Sari I, Okan T, Akar S, Cece H, Altay C, Secil M, et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 2006;45:283-6. (Pubitemid 43372841)
22. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Martin J, Llorca J. Carotid intima-media thickness and endothelial function: Useful surrogate markers for establishing cardiovascular risk in patients with inflammatory rheumatic disease. Arthritis Res Ther 2008;10:403.
23. Malesci D, Niglio A, Angela Mennillo G, Buono R, Valentini G, La Montagna G. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 2007;26:710-4. (Pubitemid 46554077)
24. Divecha H, Sattar N, Rumley A, Cherry L, Loe GD, Sturrock R. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: Relevance of systemic inflammation. Clin Sci 2005;109:171-6. (Pubitemid 41117300)
25. Joven J, Rubies-Prat J, Ras MR, de la Figuera M, Lience E, Masdeu S. High density lipoproteins cholesterol subfractions and apoprotein A-I in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum 1984;27:1199-2000.
26. Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z. The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol 2002;29:462-6. (Pubitemid 34202812)
27. Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: Acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002;4:R5.
28. Mathieu S, Hjoly H, Baron G, Tournadre A, Dubost JJ, Ristori JM, et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology 2008;47:1203-7. (Pubitemid 352038227)
29. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44. (Pubitemid 44511610)
30. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 2004;364:2021-9. (Pubitemid 39593078)
31. Davis JM 3rd, Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: A population-based cohort study. Arthritis Rheum 2007;56:820-30. (Pubitemid 46399429)
32. Bruce IN. 'Not only...but also': Factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology 2005;44:1492-502. (Pubitemid 41742464)
33. Rho YH, Oeser A, Chung CP, Milne GL, Stein CM. Drugs used in the treatment of rheumatoid arthritis: Relationship between current use and cardiovascular risk factors. Arch Drug Inf 2009;2:34-40.
34. Cui R, Iso H, Toyoshima H, Date C, Yamamoto A, Kikuchi S, et al; JACC Study Group. Serum total cholesterol levels and risk of mortality from stroke and coronary heart disease in Japanese: The JACC study. Atherosclerosis 2007;194:415-20. (Pubitemid 47513069)
35. Saiki O, Takao R, Naruse Y, Kuhara M, Imai S, Uda H. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. J Rheumatol 2007;34:1997.
36. Van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: A case control study. Arthritis Res Ther 2006;8:R151.